Ozempic itself has no BMI requirement. It’s FDA-approved for adults with type 2 diabetes, and the prescribing label doesn’t mention BMI at all. If you have type 2 diabetes, your doctor can prescribe Ozempic regardless of your weight. But if you’re asking about semaglutide for weight loss specifically, that’s where BMI thresholds come into play, and the numbers depend on your health conditions and your insurance plan.
Ozempic vs. Wegovy: Why BMI Matters for One but Not the Other
Semaglutide is the active ingredient in both Ozempic and Wegovy. Ozempic is approved for type 2 diabetes management and cardiovascular risk reduction. Wegovy is the version approved for weight management. They contain the same drug at different doses.
When people search for “what BMI to get Ozempic,” they’re usually asking about using semaglutide to lose weight. Doctors sometimes prescribe Ozempic off-label for weight loss, but the formal BMI criteria come from Wegovy’s approval and from insurance coverage rules. Here’s the standard breakdown:
- BMI of 30 or higher: You qualify based on BMI alone.
- BMI of 27 to 29.9: You qualify if you also have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol.
Interestingly, the American Diabetes Association notes that the FDA has actually removed these specific BMI thresholds from the labels of several newer obesity medications, including semaglutide. In practice, though, most insurance companies and prescribers still use 30 and 27 as their benchmarks.
Conditions That Lower the BMI Threshold to 27
If your BMI falls between 27 and 30, you’ll need a documented weight-related health condition to qualify. The conditions that most commonly count include high blood pressure, type 2 diabetes, high cholesterol or triglycerides, and obstructive sleep apnea. Some providers also consider conditions like fatty liver disease or osteoarthritis linked to excess weight.
These aren’t obscure diagnoses. Roughly half of adults in the U.S. have high blood pressure or elevated cholesterol, so many people in the 27 to 30 BMI range already have a qualifying condition without realizing it’s relevant to their eligibility.
What Insurance Companies Actually Require
Meeting the BMI threshold is just step one. Most insurance plans add their own layers of requirements before they’ll approve coverage, especially for the weight-loss indication. A representative prior authorization form from CVS Caremark, one of the largest pharmacy benefit managers, lays out what’s typical:
- Baseline BMI documentation: Your BMI at the start of treatment must be 30 or higher, or 27 or higher with a qualifying condition. If you’ve already been on another weight-loss medication, insurers often look at your BMI before you started any drug therapy, not your current weight.
- Prior lifestyle intervention: You need to have participated in a comprehensive weight management program for at least six months before drug therapy. This means a structured effort involving dietary changes, increased physical activity, and behavioral modification with documented follow-up visits.
A Tufts Medical Center analysis of U.S. commercial health plans found that most insurers follow the standard 30/27 cutoffs, but a few are more restrictive. Two plans in the study only covered patients with a BMI above 30, eliminating the 27-with-comorbidities pathway entirely. Coverage varies significantly by plan, so checking your specific formulary is essential before assuming you’re covered.
Eligibility for Adolescents
Semaglutide was approved for patients aged 12 and older in late 2022. For adolescents, BMI is measured differently because healthy weight ranges shift with age and sex. The standard is a BMI at or above the 95th percentile for the teen’s age and sex, based on CDC growth charts. Teens at or above the 85th percentile can also qualify if they have a weight-related condition like high blood pressure, abnormal cholesterol, sleep apnea, or type 2 diabetes.
Health Conditions That May Rule You Out
Even if your BMI qualifies, certain health factors can make semaglutide unsafe. The FDA label lists two absolute contraindications: a personal or family history of medullary thyroid carcinoma (a rare type of thyroid cancer) and a condition called Multiple Endocrine Neoplasia syndrome type 2. If either runs in your family, semaglutide is off the table.
A history of pancreatitis is another red flag. Semaglutide hasn’t been studied in people who’ve had pancreatitis, and prescribers are directed to consider other options for those patients. If you have a history of diabetic retinopathy, your eye health should be monitored closely during treatment, as rapid improvements in blood sugar control can sometimes cause temporary worsening of retinopathy.
Getting a Prescription Without a Diabetes Diagnosis
If you don’t have type 2 diabetes and want semaglutide for weight loss, the clearest path is through Wegovy rather than Ozempic, since Wegovy carries the FDA-approved weight management indication. Some doctors prescribe Ozempic off-label for weight loss, but insurance plans are less likely to cover it for that purpose because the approved indication is diabetes.
The practical reality: if your BMI is 30 or above, or 27 or above with a qualifying condition, and you’ve made a documented attempt at lifestyle changes for at least six months, you meet the criteria most prescribers and insurers use. If you’re below a BMI of 27 with no weight-related conditions, getting semaglutide through standard medical channels will be difficult regardless of which brand name you pursue.